10-Q/A: Allurion Restates Q1 2024 Financials, Cites Material Weaknesses

Allurion Technologies, Inc. filed an amended quarterly report to restate its Q1 2024 financial statements, revealing material weaknesses in internal controls and a significant revenue decline.

Summary

• Restated unaudited condensed consolidated financial statements for the fiscal quarter ended March 31, 2024, due to an error identified while preparing Q2 2025 financials.
• The error caused overstatements and understatements in Other comprehensive income (loss), Other income (expense), Net income (loss), Accumulated other comprehensive income (loss), and Accumulated deficit.
• The error had no impact on revenue, gross profit, operating expenses, operating profit (loss), or cash and cash equivalents.
• The error originated from existing material weaknesses related to a lack of sufficient staff with public company and technical accounting experience, and insufficient information systems controls.
• A 1-to-25 reverse stock split was effected on January 3, 2025, and financial statements have been retrospectively adjusted to reflect its effects.
• Revenue decreased by 33% to $9.4 million for the three months ended March 31, 2024, compared to $14.1 million in the same period of 2023.
• Net income for Q1 2024 was $2.0 million (restated), an improvement from a net loss of $17.8 million in Q1 2023, primarily driven by non-cash fair value adjustments.
• The company concluded there is substantial doubt about its ability to continue as a going concern for one year from the filing date due to recurring losses and expected negative operating cash flows.
• Subsequent to the quarter, Allurion issued $48 million in convertible senior secured notes to RTW, using the proceeds to repay the Fortress Term Loan in full on April 16, 2024.
• The Revenue Interest Financing Agreement with RTW was amended, increasing the royalty rate for net sales under $100 million from 6% to 12% prior to December 31, 2026, and from 10% to 12% on or after January 1, 2027.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the restatement of financials, acknowledged material weaknesses in internal controls, significant revenue decline, and the explicit statement of substantial doubt about the company's ability to continue as a going concern. While a capital raise occurred, it comes with increased royalty rates and potential future dilution, indicating ongoing financial distress.

Positives

• Net income improved to $2.0 million in Q1 2024 (restated) from a net loss of $17.8 million in Q1 2023, largely due to non-cash fair value adjustments for warrants and earn-out liabilities.
• Loss from operations improved to $(11.4) million in Q1 2024 from $(13.9) million in Q1 2023.
• Net cash used in operating activities decreased to $(8.6) million in Q1 2024 from $(10.3) million in Q1 2023.
• Sales and marketing expenses decreased by 48% to $6.2 million in Q1 2024, reflecting a reorganization and more efficient spending.
• Research and development expenses decreased by 27% to $5.7 million in Q1 2024, as the AUDACITY clinical trial nears completion.

Negatives

• Restatement of Q1 2024 financial statements due to an error in historical consolidated financial statements.
• Material weaknesses in internal control over financial reporting, specifically a lack of sufficient staff with public company and technical accounting experience, and insufficient information systems controls.
• Disclosure controls and procedures were not effective as of March 31, 2024.
• Substantial doubt about the ability to continue as a going concern for one year from the filing date.
• Revenue decreased by 33% to $9.4 million in Q1 2024, primarily due to lower re-order rates and managing credit risk with distributors.
• Gross profit decreased by 38% to $6.9 million in Q1 2024, impacted by decreased sales volume and increased manufacturing expense due to lower production.
• General and administrative expenses increased by 20% to $6.4 million in Q1 2024, driven by higher salaries, legal fees, and insurance costs.
• The royalty rate for revenue interest payments to RTW was increased from 6% to 12% (for sales under $100M prior to Dec 31, 2026) and from 10% to 12% (for sales under $100M on or after Jan 1, 2027).

Risks

• Material weaknesses in internal control over financial reporting and ineffective disclosure controls and procedures.
• Substantial doubt about the ability to continue as a going concern.
• Inability to raise additional capital or enter into financing agreements on favorable terms, or at all.
• Dependence on market acceptance and broader adoption of products by healthcare providers.
• Need for timely regulatory approvals and efficient introduction of new products.
• Fluctuations in foreign currency exchange rates impacting financial results.
• Highly competitive and rapidly changing regulated industries in which the company operates.
• Potential for litigation or claims related to intellectual property, employee matters, or adverse patient reactions.

Future Outlook

The company expects to continue generating significant operating losses for the foreseeable future and will need substantial additional funding for operating activities. It is unable to accurately predict the timing or amount of increased expenses or when, or if, profitability will be achieved or maintained.

Management Comments

• Management re-evaluated the effectiveness of disclosure controls and procedures and internal control over financial reporting as of March 31, 2024, concluding they were not effective due to material weaknesses.
• Management determined the error leading to restatement originated from existing material weakness related to the lack of sufficient levels of staff with public company and technical accounting experience to maintain proper control activities and perform risk assessment and monitoring activities.

Industry Context

Allurion operates in a highly competitive and rapidly changing medical device industry focused on weight loss. Its Allurion Program, featuring a swallowable intragastric balloon and AI-powered remote patient monitoring, positions it within the growing market for non-invasive weight management solutions. The collaboration with Medtronic plc suggests an effort to integrate its Virtual Care Suite into broader medical and surgical weight loss interventions.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings. However, the company may become involved in claims related to intellectual property, employee matters, or adverse patient reactions in the normal course of operations.

Related Party Transactions

• Consulting agreements with KKG Enterprises, LLC and Remus Group Management, LLC (affiliated with director Krishna Gupta) for AI platform development and advisory services, totaling $0.5 million in payments, terminated on June 20, 2023.
• Convertible note with Hunter Ventures Limited (HVL), a fund affiliated with director Krishna Gupta, for $13 million of 2023 Convertible Notes.
• Termination agreement with the Chief Commercial Officer, Benoit Chardon, and Benoit Chardon Consulting (BCC), involving a lump-sum termination fee of $0.2 million paid to BCC on December 12, 2023, effective December 31, 2023.

Stakeholder Impact

• Shareholders face significant risks including potential dilution from future capital raises, uncertainty due to material weaknesses in internal controls, and the explicit going concern doubt.
• Employees may experience changes in staffing and roles as the company implements remediation efforts for internal controls and reorganizes sales and marketing.
• Customers may be affected by the company's credit risk management strategies, leading to reduced product availability or changes in distribution relationships.
• Creditors (like RTW) have seen their financing terms adjusted, including increased royalty rates, reflecting the company's financial challenges and need for continued funding.

Next Steps

• Continue hiring additional accounting staff with public company experience.
• Implement a new enterprise resource planning (ERP) system.
• Implement additional review controls and processes for timely account reconciliation and transaction analysis.
• Work with a national accounting firm to assist in the design and implementation of controls and remediation of control gaps.
• Include a proposal in the definitive proxy statement on Schedule 14A seeking Stockholder Approval for the convertible notes conversion no later than December 31, 2025.
• Call special stockholder meetings every 90 days thereafter if Stockholder Approval is not obtained, until approval is secured or notes are no longer outstanding.
• Complete the AUDACITY clinical trial in the United States, with results expected to support a premarket approval submission to the FDA.

Key Dates

Recommendation

The filing reveals severe underlying issues, including a financial restatement due to material weaknesses in internal controls, a significant 33% decline in revenue, and an explicit 'going concern' warning. While a capital raise occurred, it came with less favorable terms (increased royalty rates) and potential future dilution. These factors collectively indicate substantial operational and financial distress, making the stock a high-risk investment with significant downside potential for a seasoned investor.

Keywords

Allurion Technologies, ALUR, SEC filing, 10-Q/A, financial restatement, internal controls, material weakness, going concern, weight loss, medical device, intragastric balloon, financial reporting, corporate governance, reverse stock split, capital raise, convertible notes, RTW Investments